Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

Valion Bio (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod for Acute Radiation Syndrome and oncology supportive care, will report Q1 2026 financial results after market close on May 14, 2026.

Rhea-AI Summary

Valion Bio (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod for Acute Radiation Syndrome and oncology supportive care, will report Q1 2026 financial results after market close on May 14, 2026.

Management will host a conference call and webcast, with a replay available on the investor website.

Argus May 11 session

+15.63% close to close Open Argus

Details

News Market Reaction – VBIO

On May 11, the day this news came out, VBIO closed 15.63% above the previous close.

Data tracked by StockTitan Argus for the May 11 session.

Market Context

On May 11, the day this news came out, the stock closed 15.6% above the previous close. A strong pos...

Analysis

On May 11, the day this news came out, the stock closed 15.6% above the previous close. A strong positive reaction aligns with the stock’s sensitivity to news flow, given prior moves around operational and clinical milestones. An earnings-date announcement itself did not contain financial results, so subsequent sustainability would have depended on what was later disclosed on May 14, 2026. Investors evaluating durability of any strength would typically compare it to earlier reactions near the May 4–6 news streak and watch upcoming execution milestones.

Key Figures

Earnings report date: May 14, 2026 Quarter end date: March 31, 2026 Participant access code: 118764

Earnings report date

May 14, 2026

Q1 2026 financial results to be reported after market close

Quarter end date

March 31, 2026

End of Valion Bio’s first fiscal quarter 2026

Participant access code

118764

Access code for the Q1 2026 conference call

Historical Context

3 past events · Latest: May 06

3 events

1. May 06

   Facility opening

   24h Move

   +2.0%

   Opened Velocity Bioworks facility enabling domestic Entolimod™ manufacturing.

2. May 05

   Clinical funding update

   24h Move

   -3.4%

   NIAID to fully fund BLA-enabling in vivo Entolimod™ studies.

3. May 04

   Leadership appointment

   24h Move

   -3.4%

   Appointed new General Counsel to support legal and regulatory strategy.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN ANTONIO, Texas, May 11, 2026 /PRNewswire/ -- Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO), a clinical-stage immunotherapeutics company developing Entolimod™ for Acute Radiation Syndrome (ARS) and oncology supportive care, today announced that it will report financial results for the first quarter ended March 31, 2026, after market close on Thursday, May 14, 2026.

Management will host a conference call and webcast to discuss the Company's financial results and provide a business update.

Conference Call and Webcast Details

Webcast: https://www.webcaster5.com/Webcast/Page/2865/54024
Dial-In: 888-506-0062
International: 973-528-0011
Participant Access Code: 118764

A replay of the webcast will be available on the Investors section of the Company's website following the conclusion of the event.

About Valion Bio, Inc.

Valion Bio, Inc. (formerly Tivic Health Systems, Inc.) (Nasdaq: VBIO) is a clinical-stage immunotherapeutics company developing Entolimod™, a TLR5 agonist, for Acute Radiation Syndrome (ARS), oncology supportive care, and longevity indications. Entolimod™ for ARS has received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration. Valion Bio is also advancing Entolasta™, a next-generation TLR5 agonist designed for potential broader therapeutic applications, including oncology supportive care. The Company's clinical pipeline includes potential treatments for neutropenia, which is most commonly caused by chemotherapy, and a state of T-cell dysfunction known as lymphocyte exhaustion. Valion Bio's wholly owned subsidiary, Velocity Bioworks, is a full-service contract development and manufacturing organization (CDMO) offering biomanufacturing services to third-party biotech companies. Valion Bio also leverages Velocity Bioworks' manufacturing capabilities to advance its own drug pipeline with the expected benefits of lower costs, accelerated manufacturing outcomes, and supply chain security. For more information, visit www.valionbio.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Valion Bio, Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company's interactions with and guidance from the FDA and other regulatory authorities; the continued interest of BARDA and other U.S. government agencies in Entolimod™; the ability of the company to achieve the expected benefits from the acquisition of development and manufacturing assets within expected time frames or at all; changes to the company's relationship with its partners; failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations, including related to the Animal Rule; the company's future development of Entolimod or Entolasta; changes to the company's business strategy; timing and success of pre-clinical and clinical trials and study results; regulatory requirements and pathways for approval; the company's ability to successfully commercialize its product candidates in the future; changes in the markets and industries in which the company does business; consummation of any strategic transactions; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Valion Bio's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 30, 2026, under the heading "Risk Factors", as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.

Investor + Media Contact
Rich Cockrell
CG Capital
vbio@cg.capital

View original content to download multimedia:https://www.prnewswire.com/news-releases/valion-bio-to-report-first-quarter-2026-financial-results-on-may-14-2026-302767800.html

SOURCE Valion Bio, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Valion Bio (VBIO) report its Q1 2026 financial results?

Valion Bio will report its Q1 2026 financial results after market close on May 14, 2026. According to Valion Bio, the release will be followed by a management conference call and webcast to discuss results and provide a business update.

How can investors access the Valion Bio (VBIO) Q1 2026 earnings webcast?

Investors can access the Valion Bio Q1 2026 webcast at https://www.webcaster5.com/Webcast/Page/2865/54024. According to Valion Bio, the webcast will cover financial results and a business update, with a replay later posted in the Investors section of the company website.

What are the dial-in details for Valion Bio (VBIO) Q1 2026 earnings call?

Investors can join the Valion Bio earnings call by dialing 888-506-0062 in the U.S. or 973-528-0011 internationally. According to Valion Bio, participants should use access code 118764 to join the conference call discussing Q1 2026 financial results and updates.

Will there be a replay of the Valion Bio (VBIO) Q1 2026 earnings webcast?

Yes, a replay of the Valion Bio Q1 2026 earnings webcast will be available. According to Valion Bio, investors can access the replay on the Investors section of the company’s website after the live event concludes, enabling on-demand review of results and commentary.

What does Valion Bio (VBIO) develop with its Entolimod program?

Valion Bio is developing Entolimod for Acute Radiation Syndrome and oncology supportive care. According to Valion Bio, the company is a clinical-stage immunotherapeutics developer, and its Q1 2026 update may provide broader business context alongside the financial discussion on the call.